Difference between revisions of "Cutaneous T-cell lymphoma - null regimens"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="width: 100%" to "{| class="wikitable sortable" style="width: 100%") |
Warner-admin (talk | contribs) m (Text replacement - "http://jco.ascopubs.org/content/28/11/1870.long" to "https://doi.org/10.1200/jco.2009.26.2386") |
||
| Line 19: | Line 19: | ||
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
| − | |[ | + | |[https://doi.org/10.1200/jco.2009.26.2386 Prince et al. 2010 (L4389-11)] |
|NR | |NR | ||
|style="background-color:#1a9851"|Phase III (C) | |style="background-color:#1a9851"|Phase III (C) | ||
| Line 28: | Line 28: | ||
===References=== | ===References=== | ||
<!-- Presented in part at the 43rd Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL; and the 44th Annual Meeting of the American Society of Clinical Oncology, May 30-June 3, 2008, Chicago, IL. --> | <!-- Presented in part at the 43rd Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL; and the 44th Annual Meeting of the American Society of Clinical Oncology, May 30-June 3, 2008, Chicago, IL. --> | ||
| − | # '''L4389-11:''' Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010 Apr 10;28(11):1870-7. Epub 2010 Mar 8. [ | + | # '''L4389-11:''' Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010 Apr 10;28(11):1870-7. Epub 2010 Mar 8. [https://doi.org/10.1200/jco.2009.26.2386 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/20212249 PubMed] |
[[Category:Cutaneous T-cell lymphoma regimens]] | [[Category:Cutaneous T-cell lymphoma regimens]] | ||
Revision as of 00:38, 1 April 2021
The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main CTCL page for current regimens.
Relapsed or refractory
Placebo
| back to top |
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Prince et al. 2010 (L4389-11) | NR | Phase III (C) | Denileukin diftitox | Inferior PFS |
References
- L4389-11: Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010 Apr 10;28(11):1870-7. Epub 2010 Mar 8. link to original article contains verified protocol PubMed